Internet Archive Scholar

Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy

C Fielder Camm, A John Camm, University of Oxford, Oxford, St George's, University of London, Imperial College, London, UK
2017 Arrhythmia & Electrophysiology Review  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (843.4 kB)
https://web.archive.org/web/20190428124500/https://www.aerjournal.com/system/files/articles/AER-6-2_63-8.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Hypertrophic cardiomyopathy (HCM) represents a common inherited cardiac disorder with well-known complications including stroke and sudden cardiac death. There is a recognised association between HCM and the development of AF. This review describes the epidemiology of AF within the HCM population and analyses the risk factors for the development of AF. It further discusses the outcomes associated with AF in this population, including the evidence in support of higher stroke risk in patients
more » ... HCM with AF compared with the general AF population. Finally, the evidence and recommendations for anticoagulation in this patient group are addressed.
doi:10.15420/aer.2017:4:2 fatcat:5tljxxnro5erfdnerzlcqrbsl4
DOAJ
Citation

C Fielder Camm, A John Camm, University of Oxford, Oxford, St George's, University of London, Imperial College, London, UK. "Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy." Arrhythmia & Electrophysiology Review 6.2 (2017) 63